Treating Clostridium difficile Infection with Fecal Microbiota Transplantation

By J. Bakken, T. Borody, L. Brandt, J. Brill, D. Demarco, M. A. Franzos, C. Kelly, A. Khoruts, T. Louie, Lawrence P. Martinelli and 3 more. Clinical Gastroenterology and Hepatology, 2011

972 citations recorded by the source corpus.

Clostridium difficile infection is increasing in incidence, severity, and mortality. Treatment options are limited and appear to be losing efficacy. Recurrent disease is especially challenging; extended treatment with oral vancomycin is becoming increasingly common but is expensive. Fecal microbiota transplantation (FMT) is safe, inexpensive, and effective; according to case and small series reports, about 90% of patients are cured. We discuss the rationale, methods, and use of FMT.

Subfields: Epidemiology, Infectious Diseases, Surgery

View Paper: https://www.semanticscholar.org/paper/76bd565c2071b5eb14d8f30a0d77e7ae2bfa70cd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. João B. Xavier
2. Eric G. Pamer
3. A. Khoruts

In Infectious Diseases

1. Eric G. Pamer
2. A. Khoruts
3. T. Borody

In Surgery

1. Eric G. Pamer
2. A. Khoruts
3. T. Borody

Citations in the corpus

• Ecological Modeling from Time-Series Inference: Insight into Dynamics and Stability of Intestinal Microbiota (2013, background): “the reestablishment of a patient’s intestinal microbiota by introducing the microbiota of a healthy donor, is highly effective against Clostridium difficile induced colitis [23,24].”
• Fecal microbiota transplantation and emerging applications (2012, background): “More recently, a group of international infectious disease and gastroenterology specialists have published formal standard practice guidelines for performing FMT in CDI, outlining the rationale, methods and use of FMT, including screening procedures, material preparation, FMT administration and othe”
• The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation (2016, background): “difficile with a cure rate higher than 90 % [92].”